All clinical trials must have a written Data and Safety Monitoring (DSM) plan. Many clinical trials activated at the Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) are multicenter trials and have a DSM plan that has been previously approved by an appropriate authority external to VCU. Although not required by NCI CCSG guidelines or NCI/NIH policy, the MCC default DSM plan for clinical trials is a DSMB. DSMBs evaluate ongoing trials for data integrity and subject safety. DSMB recommendations are reported to investigators and the IRB. If a DSMB identifies problems so serious as to raise doubts about the meaningfulness of the results of a trial, it also reports its findings to the Protocol Review and Monitoring Committee (PRMC). Although DSMBs make recommendations, the DSMB function is an advisory function. In addition to the DSMB, a DSM plan generally contains two other components: the Study Team and an Audit Committee (AC). The Study Team is the group primarily responsible for study conduct. In most cases, the study team consists of the Investigator(s), Study Biostatistician, a Research Nurse, a Clinical Research Associate, and a Regulatory Expert. Study teams meet regularly as appropriate for an individual study. ACs audit trials for regulatory compliance, protocol compliance, and data quality. AC findings are reported to the investigator and the trial DSMB. Although the AC may make recommendations, the AC function is a fact finding function.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016059-33
Application #
8662714
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
33
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Wu, Xiaowei; Guan, Ting; Liu, Dajiang J et al. (2018) ADAPTIVE-WEIGHT BURDEN TEST FOR ASSOCIATIONS BETWEEN QUANTITATIVE TRAITS AND GENOTYPE DATA WITH COMPLEX CORRELATIONS. Ann Appl Stat 12:1558-1582
Chawla, Ayesha T; Cororaton, Agnes D; Idowu, Michael O et al. (2018) An intestinal stem cell niche in Apc mutated neoplasia targetable by CtBP inhibition. Oncotarget 9:32408-32418
Zarate-Perez, Francisco; Velázquez-Fernández, Jesús B; Jennings, Gareth K et al. (2018) Biophysical characterization of Aptenodytes forsteri cytochrome P450 aromatase. J Inorg Biochem 184:79-87
Montefusco, David J; Allegood, Jeremy C; Spiegel, Sarah et al. (2018) Non-alcoholic fatty liver disease: Insights from sphingolipidomics. Biochem Biophys Res Commun 504:608-616
Yamada, Akimitsu; Nagahashi, Masayuki; Aoyagi, Tomoyoshi et al. (2018) ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. Mol Cancer Res 16:1059-1070
Cantwell, Marc T; Farrar, Jared S; Lownik, Joseph C et al. (2018) STAT3 suppresses Wnt/?-catenin signaling during the induction phase of primary Myf5+ brown adipogenesis. Cytokine 111:434-444
Aqbi, Hussein F; Wallace, Matthew; Sappal, Samay et al. (2018) IFN-? orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol :
Volker, Sonja E; Hedrick, Shannon E; Feeney, Yvonne B et al. (2018) Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland. Cancer Res 78:3877-3887
Li, Xiaojiaoyang; Liu, Runping; Huang, Zhiming et al. (2018) Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology 68:599-615
Durant, Stephen T; Zheng, Li; Wang, Yingchun et al. (2018) The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv 4:eaat1719

Showing the most recent 10 out of 586 publications